Search

Search Constraints

You searched for: Author/Creator Comi, Giancarlo

Search Results

1. 016  Long-term disease stability in patients treated with cladribine tablets in CLARITY and CLARITY extension. Issue 6 (27th May 2022)

2. 022  Updated safety of cladribine tablets in multiple sclerosis patients: integrated safety analysis and post-approval data. Issue 6 (27th May 2022)

3. 039 Rates of lymphopenia in years 1–4 in patients with relapsing multiple sclerosis treated annually with cladribine tablets. Issue 6 (24th May 2018)

4. 040 An analysis of malignancy risk in the clinical development programme of cladribine tablets in patients with relapsing multiple sclerosis. Issue 6 (24th May 2018)

5. 066 Impact of long-term teriflunomide treatment on lymphocyte counts and infections in pooled temso and tower studies. Issue 6 (24th May 2018)

6. 067 Efficacy of cladribine tablets in patients with highly active relapsing-remitting multiple sclerosis: analysis of pooled double-blind data from the clarity and onward studies. Issue 6 (24th May 2018)

7. 067 Neurofilament light chain concentration predicts risk of relapse in participants with relapsing multiple sclerosis in phase 3 ozanimod trials. (23rd August 2021)

8. 1298Associations of DMT therapies with COVID-19 severity in multiple sclerosis. (2nd September 2021)

9. A pharmacogenetic study implicates NINJ2 in the response to Interferon-β in multiple sclerosis. (August 2020)

10. A pharmacogenetic study implicates SLC9a9 in multiple sclerosis disease activity. Issue 1 (14th May 2015)